Date: 2016-07-21
Type of information: Collaboration agreement
Compound: Entericolix© vaccine
Company: Boehringer Ingelheim (Germany) CZ Veterinaria (Spain)
Therapeutic area: Veterinary medicine
Type agreement: collaboration
Action mechanism: vaccine. The vaccine contains inactivated strains of Escherichia coli expressing the adhesins F4ac, F5, F6, F18ab, F18ac and F41 which cause neonatal enterotoxicosis in piglets, as well as ?-enterotoxin from Clostridium perfringens type C. The vaccine is formulated with an oily adjuvant. In sows and gilts, the vaccine induces the specific seroconversion of vaccinated animals; piglets are passively immunised by intake of colostrum containing Escherichia coli adhesin-specific and Clostridium perfringens anti-enterotoxin antibodies.
Disease: prevention of diarrhoea in piglets caused by E. coli. and C. perfringens Type C
Details: * On July 21, 2016, CZ Veterinaria (CZV) and Boehringer Ingelheim Animal Health announced that both companies have entered into a cooperation to provide Entericolix®, an innovative sow vaccine, to the European swine vaccine market. CZV has developed and registered Entericolix® in Europe; Boehringer Ingelheim Animal Health will use its strong swine distribution network and technical support to provide the vaccine to customers. The European National Authorities have approved Entericolix® which is unique in providing a 21 days duration of immunity against diarrhoea in piglets caused by E. coli. and C. perfringens Type C. The vaccine reduces mortality and clinical signs caused by E. coli neonatal diarrhoea and Necrotic Enteritis. Entericolix® has the unique claim of extending this protection to piglets until 21 days of age, even after the pigs were weaned. Furthermore, it provides protection against early onset of Oedema Disease caused by F18 E. coli up to 28 days of age (7 days after weaning). Oedema Disease is a naturally occurring post weaning piglet disease seen after infection with certain strains of E. coli that can lead to neurological signs and death. The Entericolix© vaccine has been successfully registered through the decentralized procedure in 20 European countries. Specific details of the agreement were not disclosed. Entericolix© is a trade mark of CZ Veterinaria.
Financial terms:
Latest news:
